| CANNABIS: 
 
 THE SCIENTIFIC AND MEDICAL EVIDENCE
 
 
 CHAPTER 1 INTRODUCTION
   1.1     Cannabis has been used medically for thousands
        of years in oriental and Middle Eastern countries and as an intoxicant for many hundreds
        of years in India and in the Middle East; and it was employed in Western medicine for at
        least two millennia. The medical use of cannabis in Europe and North America, however,
        declined in this century because of the lack of any standardised preparations of the plant
        product and its unreliable absorption when given by mouth, and because of the development
        of more potent and reliable drugs for the conditions for which cannabis was then being
        used.    1.2     During the 1960s and 1970s there was a large
        increase in the use of smoked cannabis as an intoxicant in the USA and in Europe, where it
        had been largely unknown previously as a drug of abuse. The recreational use of cannabis
        has continued to increase in recent years, particularly among the young. Medical use in
        the United Kingdom was prohibited in 1973; but cannabis is now the most widely used of all
        illegal intoxicants.    1.3     During the 1980s and 1990s there has been
        renewed interest in the potential medical uses of cannabis and its derivatives.
        Substantial numbers of patients with various conditions are illegally selfmedicating
        with cannabis and are convinced that they derive medical benefitalthough scientific
        evidence for or against such a conclusion is largely lacking. This has led to calls for
        cannabis again to be made available for medical applications.    1.4     In Britain this debate has led a number of
        expert bodies to review the medical and scientific evidence for and against such
        proposals. The British Medical Association published a report on the topic in 1997[1]. The Department of Health recently commissioned
        three literature reviews on cannabis, at the request of the Advisory Council on the Misuse
        of Drugs (ACMD); we have seen these (they were placed in the Library of the House on
        9 June), and the authors have all given evidence to this inquiry[2]. Reports were also published last year by the US National Institutes
        of Health and the American Medical Association[3].    1.5     In the light of this heightened interest in
        cannabis, and particularly the report by the BMA, we decided to examine the scientific and
        medical evidence to determine whether there was a case for relaxing some of the current
        restrictions on the medical uses of cannabis. We have also considered whether the
        continued prohibition of recreational use is justified on the basis of the scientific
        evidence of adverse effects. Recreational use raises other issues besides the adverse
        effects of the drug; these are outside our remit "to consider science and
        technology", belonging instead to the realms of law, sociology and even philosophy,
        and we have not considered them. Neither have we considered whether cannabis is a stepping
        stone or gateway to other more dangerous drugs; we have confined our considerations solely
        to cannabis.    1.6     Chapters 2 and 3 of this Report are
        introductory, giving brief accounts of the history of cannabis and its pharmacology. In
        Chapters 4-7 we review the evidence which we have received on the four key issues: the
        adverse effects of taking cannabis; current and proposed medical uses; recreational use;
        and the implications of possible changes to the law. Our conclusions and recommendations
        are set out in Chapter 8.    1.7     This report was prepared by Sub-Committee I,
        whose members are listed in Appendix 1. They received evidence from the persons and
        organisations listed in Appendix 2, to all of whom we are grateful for their help. We are
        particularly grateful to the Sub-Committee's Specialist Adviser, Professor Leslie Iversen
        FRS, Visiting Professor of Pharmacology at the University of Oxford. Professor Iversen
        attended two international conferences on the Sub-Committee's behalf; his accounts of
        these appear in Appendices 3 and 4. Abbreviations are listed in Appendix 5.    1.8     We also acknowledge the assistance of the
        Parliamentary Office of Science and Technology (POST). POST's report Common Illegal
        Drugs and their Effects (May 1996), and POST note 113 Cannabis Update (March
        1998), have been particularly helpful.
 
 
 1   Therapeutic uses of cannabis, BMA/Harwood Academic
        Publishers, 1997, ISBN 90-5702-318-0. Back2   Cannabis: clinical and pharmacological aspects, by
        Prof C H Ashton; Psychiatric aspects of cannabis use, by Dr A Johns; Therapeutic
        aspects of cannabis and cannabinoids, by Dr P Robson. Back
 3   NIH Report on the medical uses of marijuana, August
        1997; AMA Medical Marijuana, December 1997. Back
 
 |